CL2016002873A1 - Composición farmacéutica para reducir el daño talámico. - Google Patents

Composición farmacéutica para reducir el daño talámico.

Info

Publication number
CL2016002873A1
CL2016002873A1 CL2016002873A CL2016002873A CL2016002873A1 CL 2016002873 A1 CL2016002873 A1 CL 2016002873A1 CL 2016002873 A CL2016002873 A CL 2016002873A CL 2016002873 A CL2016002873 A CL 2016002873A CL 2016002873 A1 CL2016002873 A1 CL 2016002873A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
damage
thalamic damage
reduce
reduce thalamic
Prior art date
Application number
CL2016002873A
Other languages
English (en)
Inventor
Massimo Filippi
Giancarlo Comi
Maria Assunta Rocca
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of CL2016002873A1 publication Critical patent/CL2016002873A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)

Abstract

COMPOSICION FARMACEUTICA QUE COMPRENDE LAQUINIMOD PARA EL USO EN INHIBIR O REDUCIR DAÑO TALAMICO EN VALOR DE REFERENCIA EN UN SUJETO AFECTADO CON UNA ENFERMEDAD O TRASTORNO DIFERENTE A UNA FORMA DE ESCLEROSIS MULTIPLE O UN SINDROME CLINICAMENTE AISLADO, O PARA INHIBIR O REDUCIR TEMBLORES O ESPASTICIDAD.
CL2016002873A 2012-10-12 2016-11-11 Composición farmacéutica para reducir el daño talámico. CL2016002873A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261713256P 2012-10-12 2012-10-12

Publications (1)

Publication Number Publication Date
CL2016002873A1 true CL2016002873A1 (es) 2017-04-17

Family

ID=50475887

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015000732A CL2015000732A1 (es) 2012-10-12 2015-03-23 Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica.
CL2016002873A CL2016002873A1 (es) 2012-10-12 2016-11-11 Composición farmacéutica para reducir el daño talámico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2015000732A CL2015000732A1 (es) 2012-10-12 2015-03-23 Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica.

Country Status (18)

Country Link
US (2) US20140107154A1 (es)
EP (1) EP2961406A4 (es)
JP (1) JP2015533163A (es)
KR (1) KR20150080509A (es)
CN (1) CN105263325A (es)
AR (1) AR092993A1 (es)
AU (2) AU2013329348A1 (es)
BR (1) BR112015007782A2 (es)
CA (1) CA2884272A1 (es)
CL (2) CL2015000732A1 (es)
EA (1) EA201590726A1 (es)
HK (1) HK1218865A1 (es)
IL (1) IL237745A0 (es)
MX (1) MX2015004564A (es)
PE (1) PE20151435A1 (es)
SG (1) SG11201501874TA (es)
TW (1) TW201420101A (es)
WO (1) WO2014058979A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
WO2014127139A1 (en) * 2013-02-15 2014-08-21 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
TW201609098A (zh) * 2013-12-20 2016-03-16 泰瓦藥品工業有限公司 拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於延緩亨丁頓舞蹈症進展的用途
KR20170005434A (ko) 2014-04-29 2017-01-13 테바 파마슈티컬 인더스트리즈 리미티드 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드
HK1249847A1 (zh) 2015-03-09 2018-11-16 Intekrin Therapeutics, Inc. 用於治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
US20190224186A1 (en) * 2016-09-13 2019-07-25 Intekrin Therapeutics, Inc. Treatment of multiple sclerosis with chs-131
KR20200036808A (ko) 2017-04-03 2020-04-07 코히러스 바이오사이언시스, 인크. 진행성 핵상 마비 치료를 위한 PPARγ 작용제
CN113397757A (zh) * 2021-06-07 2021-09-17 温州医科大学 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
RU2009105179A (ru) * 2006-07-17 2010-08-27 Новартис АГ (CH) Сульфониламинокарбонилпроизводные амидов холевой кислоты для применения в качестве иммуномодуляторов
TW201438738A (zh) * 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
EP2442651B1 (en) * 2009-06-19 2015-07-29 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
CA2771203C (en) * 2009-08-10 2019-04-09 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
WO2011086470A1 (en) * 2010-01-13 2011-07-21 Ramot At Tel-Aviv University Ltd Treatment of multiple sclerosis
CA2820586A1 (en) * 2010-12-07 2012-06-14 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
WO2012131539A1 (en) * 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
EP2766020A4 (en) * 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
AR090885A1 (es) * 2012-05-02 2014-12-10 Teva Pharma Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple

Also Published As

Publication number Publication date
KR20150080509A (ko) 2015-07-09
IL237745A0 (en) 2015-05-31
US20140107154A1 (en) 2014-04-17
SG11201501874TA (en) 2015-05-28
AU2017203896A1 (en) 2017-06-29
BR112015007782A2 (pt) 2017-07-04
EP2961406A2 (en) 2016-01-06
CL2015000732A1 (es) 2015-08-07
EP2961406A4 (en) 2017-01-04
MX2015004564A (es) 2015-07-21
PE20151435A1 (es) 2015-10-15
CN105263325A8 (zh) 2017-07-14
CN105263325A (zh) 2016-01-20
JP2015533163A (ja) 2015-11-19
EA201590726A1 (ru) 2015-10-30
TW201420101A (zh) 2014-06-01
AR092993A1 (es) 2015-05-13
WO2014058979A2 (en) 2014-04-17
US20160296511A1 (en) 2016-10-13
WO2014058979A3 (en) 2015-08-20
HK1218865A1 (zh) 2017-03-17
CA2884272A1 (en) 2014-04-17
AU2013329348A1 (en) 2015-05-28
WO2014058979A8 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
PE20151435A1 (es) Laquinimod para reducir el dano talamico en la esclerosis multiple
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
IL244240B (en) Aminoheteroaryl benzamides as kinase inhibitors
BR112015002738A2 (pt) composto , e , composição farmacêutica
IL238958A0 (en) Glutamase inhibitors, compositions comprising same and uses thereof
CL2014002589A1 (es) Compuestos inhibidores de beta-lactamasas derivados de 7-oxo-1,6-diazabiciclo[3.2.1] octano; composicion farmaceutica que los comprende y uso para tratar una infeccion bacteriana.
BR112015000420A2 (pt) composto, composição farmacêutica, e, uso de um composto
GB2529325B (en) Multi-tenancy support for enterprise social business computing
EP3059271A4 (en) Fluorine-containing compound, composition for forming hard coat layer, and article having hard coat layer
MX2013012000A (es) Composicion y metodo para formar una superficie auto-descontaminante.
CL2015001116A1 (es) Composición y uso de dimeros de alquil cetena hidrogenados.
HUE045492T2 (hu) Porlasztható, helyileg alkalmazható hordozóanyag és foszfatidilkolint tartalmazó készítmény
BR112014016635A2 (pt) composto, composição, e, uso de um composto
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
EP3000094A4 (en) Medication workflow management
CL2016001570A1 (es) Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
BR112014000232A2 (pt) primeira composição, segunda composição e artigo
HRP20130082A2 (hr) Farmaceutski pripravak za produljeno oslobađanje trimetazidina
BR112014032501A2 (pt) composto, e, composição farmacêutica.
BR112015002646A2 (pt) composto e composição farmacêutica
BR112013019061A2 (pt) composto inibidor da caspase-2, composição farmacêutica e uso de um composto
BR112016008035A2 (pt) composição, uso da composição
BR112014016122A2 (pt) composto, e, composição farmacêutica
BR112013019283A2 (pt) composto, fármaco, composição farmacêutica e uso